advertisement
Abstract #108712 Published in IGR 23-4
Spotlight on Schlemm's Canal MicroStent Injection in Patients with Glaucoma
Wagner IV; Ang B; Checo L; Simsek D; Draper C; Dorairaj SClinical Ophthalmology 2023; 17: 1557-1564
Minimally invasive glaucoma surgery (MIGS) has revolutionized glaucoma care with its favorable safety profile and ability to delay or minimize the need for traditional, bleb-based procedures. Microstent device implantation is a type of angle-based MIGS, which reduces intraocular pressure (IOP) through bypass of the juxtacanalicular trabecular meshwork (TM) and facilitation of aqueous outflow into the Schlemm's canal. Although there are limited microstent devices on the market, multiple studies have evaluated the safety and efficacy of iStent (Glaukos Corp.), iStent Inject (Glaukos Corp.), and Hydrus Microstent (Alcon) in the treatment of mild-to-moderate open-angle glaucoma, with and without concurrent phacoemulsification. This review attempts to provide a comprehensive evaluation of injectable angle-based microstent MIGS devices in the treatment of glaucoma.
Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.
Full article